Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., Jakovljevic, M., Khader, Y., Linn, S., Lad, D., Mantovani, L., Vuong Minh Nong, Mokdad, A., Naghavi, M., Postma, M., Roshandel, G., Shackelford, K., Sisay, M., Cuong Tat Nguyen, Tung Thanh Tran, Bach Tran Xuan, Ukwaja, K. N., Vollset, S. E., Weiderpass, E., Libby, E. N. & Fitzmaurice, C., Sep-2018, In : JAMA oncology. 4, 9, p. 1221-1227 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
- PharmacoTherapy, Epidemiology and Economics
- Value, Affordability and Sustainability (VALUE)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Microbes in Health and Disease (MHD)
- Methods in Medicines evaluation & Outcomes research (M2O)
- Pharmacoepidemiology and Pharmacoeconomics
INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care.
OBJECTIVE To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016.
DESIGN AND SETTING We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates. We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region. We collected data on approval of lenalidomide and bortezomib worldwide.
MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year.
RESULTS Worldwide in 2016 there were 138 509 (95% uncertainty interval [UI], 121 000-155 480) incident cases of MM with an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95% UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106% to 192% for all SDI quintiles. The 3 world regions with the highest ASIR of MM were Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95% UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively.
CONCLUSIONS AND RELEVANCE Incidence of MM is highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.
|Number of pages||7|
|Publication status||Published - Sep-2018|
- TRANSPLANTATION, LENALIDOMIDE, GUIDELINES, RISK